Taizhou's 14 pilot plants gain provincial acclaim

A technician from Jiangsu Baoze Biotechnology prepares and develops enzymes at Huatai Vaccine's biopharmaceutical research pilot plant in Taizhou. [Photo/ourjiangsu.com]

The Jiangsu Provincial Department of Industry and Information Technology recently announced the manufacturing pilot plant cultivation library in the province, with 14 platforms in Taizhou having been selected.

In recent years, Taizhou has nurtured a group of pilot plants with prominent public attributes, leading capabilities, wide-ranging influence, and significant service effects.

The 14 selected platforms include the Taixing Economic Development Zone Pilot Incubation Industrial Park and Jiangsu Huatai Vaccine Engineering Technology Research's biopharmaceutical research pilot plant, covering multiple key areas such as pharmaceuticals, power equipment, petrochemicals, inorganic non-metals, and light industry.

Huatai Vaccine's biopharmaceutical research pilot plant, for example, spans a total area of 11,000 square meters, with an investment of 40 million yuan ($5.46 million) in equipment. The platform can carry out pilot production of the vast majority of bioproducts.

Fifty-three biopharmaceutical-related enterprises have collaborated with the pilot plant to research pilot processes and prepare clinical samples for more than 80 batches. They have obtained approvals for five first-class innovative drugs, 48 authorized invention patents, and 18 clinical trial approvals. The expected market sales of new drug products upon market entry are expected to exceed 10 billion yuan.